ARCHIVES

Guest Editorial: The Walue of Quality of Life Data In Judging Patient Benefit: experts Respond To ODAC

This article is from The Cancer Letter archive.

Vol. 25 No. 33 | September 3, 1999

Download PDF Visit The Full Archive

Related Articles

Review Of Organ Site Program Requested By NCAB Set For Nov. 23-25; Eight Member Committee Named

August 21, 1981

Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer

November 28, 2014

In Congress: Conferees Approve 42 billion Increase For NIH Appropriations

October 29, 1999

GAO Recommends Tighter Policies on NIH Recusals.

June 29, 2007

Boyd’s Rebuttal to DePinho’s Letter to the AAUP

May 30, 2014

FDA News: FDA Eases Two-Trial Standard For Proof Of Drug Efficacy

March 21, 1997